Sunday, February 26, 2017 2:24:32 PM
Percentage of women that stopped bleeding
Proellex-6mg 88% 12mg 94%
Esmya --5mg 48% 10mg 57%
Quality of life percentage improvement
Proellex---70%
Esmya------56%
The study included 432 U.S. patients with 162 and 157 patients randomized to ulipristal acetate 5 and 10 mg respectively, and 113 to placebo. The average age of patients enrolled was 41 years and 67 percent of enrolled patients were Black/African Americans. The study met all the co-primary and secondary endpoints with both ulipristal treatment arms achieving statistically significant results over placebo (p<0.0001). The co-primary efficacy endpoints were percentage of patients with absence of uterine bleeding and time to absence of uterine bleeding on treatment during Treatment Course One (12-week duration). Significantly more patients in the 10 mg group (54.8%) and the 5 mg group (42.0%) achieved absence of bleeding compared to placebo (0%).
The secondary efficacy endpoints were the percentage of patients with absence of uterine bleeding from Day 11 to end of the first treatment course; the percentage of patients with absence of uterine bleeding after the second treatment course; time to absence of uterine bleeding on treatment during treatment course two; and the change from baseline in the UFS-QOL revised Activities subscale at the end of the first treatment course.
More patients in the 10 mg group (55.4%) and the 5 mg group (34.6%) achieved absence of bleeding within 10 days after treatment initiation in Treatment Course One compared to placebo (0.0%). Significantly more patients in the 10 mg group (57.3%) and the 5 mg group (40.5%) achieved absence of bleeding compared to placebo (8.0%) in Treatment Course Two. The improvement from baseline in the UFS-QOL revised activities subscale was significantly greater in the 10 mg group (56.7%) and the 5 mg group (48.3%) compared to placebo (13.0%).
The UFS-QOL is a validated fibroid-specific symptom and health-related quality of life instrument. This questionnaire is an established instrument to assess disease impact on the well-being of women with uterine fibroids.
"It is indeed very encouraging that we have another successful phase III study conducted in patients with uterine fibroid symptoms, which shows that ulipristal acetate could bring promising treatment for women suffering from this condition," added Dr István Greiner, Research Director of Gedeon Richter Plc. "We remain committed to the development of female healthcare products aiming towards the improvement of the quality of life of women in all age groups."
The most common adverse events (≥5%) on ulipristal acetate treatment were hot flush, headache, fatigue, and nausea in the combined period of Treatment Course One and first off-treatment interval. The most common adverse event (≥ 5%) on ulipristal acetate treatment was headache in the combined period of Treatment Course Two and second off-treatment interval.
Recent RPRX News
- Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024 • GlobeNewswire Inc. • 04/19/2024 12:15:00 PM
- Royalty Pharma Declares Second Quarter 2024 Dividend • GlobeNewswire Inc. • 04/17/2024 12:15:00 PM
- Royalty Pharma to Present at TD Cowen’s 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/28/2024 09:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/15/2024 02:05:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 12:33:43 PM
- Royalty Pharma Reports Q4 and Full Year 2023 Results • GlobeNewswire Inc. • 02/15/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2024 12:01:30 PM
- Royalty Pharma To Announce Fourth Quarter And Full Year 2023 Financial Results On February 15, 2024 • GlobeNewswire Inc. • 01/30/2024 09:15:00 PM
- Royalty Pharma Announces Dividend Increase • GlobeNewswire Inc. • 01/19/2024 01:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 12:18:52 PM
- Royalty Pharma Highlights Accomplishments and Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/08/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 09:31:02 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/03/2024 09:30:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 09:29:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/27/2023 09:31:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/27/2023 06:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 09:30:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:31:02 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/13/2023 09:47:54 PM
- Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx Conference • GlobeNewswire Inc. • 11/27/2023 09:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:16:52 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 11/16/2023 10:13:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/15/2023 12:35:11 AM
- Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program • GlobeNewswire Inc. • 11/13/2023 01:10:00 PM
- Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program • Business Wire • 11/13/2023 01:00:00 PM
FEATURED Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • Apr 25, 2024 8:52 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM